Table 3

Crude incidence, rate of attrition and Kaplan-Meier survival estimates of children followed in the Orotta National Paediatric Referal Hospital (ONPRH) cART treatment centre, Asmara, Eritrea (2005–2020)

Cohort characteristicsIncidence of attrition per 100 person years (95% CI)Mean survival duration in years (95% CI)P value (log-rank)
Total3.2 (2.7 to 3.7)14.1 (13.4 to 14.8)
Gender
 Male3.8 (31. to 4.6)13.2 (2.1 to 14.3)0.008 (6.9)
 Female2.5 (2 to 3.2)13.8 (13.1 to 14.4)
Age in years at enrolment
 ≤52.5 (1.9 to 3.2)15.1 (14.2 to 16)<0.001 (36.8)
 6–102.8 (2.2 to 3.6)11.7 (11.1 to 12.2)
 >106.7 (5 to 8.9)8.4 (7.43 to 9)
Residence0.002 (9.8)
 Maekel2.7 (2.3 to 3.3)14.6 (13.8 to 15.4)
 Outside Maekel4.6 (3.5 to 5.9)10.9 (10 to 11.7)
Disease stage at presentation<0.001 (22)
 Early1.4 (0.9 to 2.1)15 (14.2 to 15.7)
 Advanced3.9 (3.3 to 4.6)13.2 (12.3 to 14)
TB status0.2 (1.5)
 Symptomatic and under treatment3.1 (2.6 to 3.7)9.9 (6.9 to 12.8)
 Not symptomatic6.5 (2.7 to 15.8)14 (13.3 to 14.8)
 Haemoglobin0.004 (8.3)
 Anaemia2.2 (1.7 to 2.9)11.5 (11 to 12)
 Normal3.7 (2.9 to 4.7)12.8 (12 to 13)
WAZ0.014 (6)
 WAZ ≥−22.1 (1.48 to 3.1)13 (12.4 to 13.7)
 WAZ <−23.5 (2.8 to 4.4)12 (11.4 to 12.8)
HAZ0.019 (5.4)
 HAZ ≥−22.3 (1.7 to 3.2)14.9 (13.7 to 16)
 HAZ <−23.5 (3 to 4.2)12.7 (12 to 13.4)
BAZ<0.001 (12.4)
 BAZ ≥−22.4 (1.9 to 3)15 (14 to 15.9)
 BAZ <−24.4 (3.5 to 5.5)12 (11 to 13)
Initial cART backbone<0.001 (54.5)
 AZT+3TC2.3 (1.9 to 2.8)13.9 (13.4 to 14.5)
 Other backbones7.1 (5.6 to 9)11.3 (9.8 to 12.8)
NNRTI0.9 (0.015)
 Efavirenz (EFV)3.2 (2.6 to 3.9)13 (12.3 to 13.7)
 Nevirapin (NVP)3 (2.5 to 3.9)14.2 (13.3 to 15.2)
Current cART regimen
 First-line cART3.34 (2.8 to 3.9)12.9 (12.3 to 13.4)0.15 (2)
 Second-line cART2.2 (1.3 to 3.7)15.7 (14.3 to 17)
Adherence0.68 (0.16)
 Suboptimal adherence2.9 (1.9 to 4.3)12.6 (11.8 to 13.4)
 No record3.2 (2.7 to 3.7)14.3 (13.6 to 15)
cART change<0.001 (136)
 cART change1 (0.84 to 1.3)13.6 (13 to 14)
 No cART change2 (1.7 to 2.5)7.5 (6.6 to 8.4)
  • Comparisons of survival duration were performed by using the log-rank test and its p value.

  • Other backbones refer to tenofovir disoproxil fumarate+emtricitabine, abacavir+3TC or stavudine+3TC. Anaemia was defined as haemoglobin level <11 g/dL for children <5 years old, <11.5 g/dL for children 5–11.9 years old and <12 g/dL for children >12 years old.

  • AZT+3TC, zidovudine+lamivudine; BAZ, body mass index-for-age z-score; cART, combined antiretroviral therapy; HAZ, height-for-age z-score; NNRTI, non-nucleoside reverse transcriptase inhibitor; TB, tuberculosis; WAZ, weight-for-age z-score.